Minerva Neurosciences appoints Dr. Kuchibhatla as SVP Head of R&D; Dr. Saoud to advisory role

Minerva Neurosciences, Inc.

Dr. Jay Saoud resigns as SVP Head of R&D effective Sept 15, 2021; transitions to consultant through June 2022.
Dr. Ramana Kuchibhatla appointed as Senior VP & Head of R&D effective Sept 16, 2021, reporting to CEO.
Saoud will continue supporting preparation and submission of NDA for roluperidone (negative symptoms of schizophrenia).
Consulting fee: $412.50/hr first 20 hrs/wk, $500/hr beyond; equity awards accelerate upon completion or early termination.
Kuchibhatla has over 35 years drug development experience from PRA Health Sciences, Melior, Targacept, GSK.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.